Janssen had better Darzalex sales than expected in Q1

US pharmaceutical company Jansssen holds the rights for Darzalex, which was developed by Danish biotech firm Genmab and has had significantly better sales than expected in this year's first quarter.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen receives new approval for Darzalex in Canada
For subscribers